CRNX News

$CRWV Investor Notification: CoreWeave, Inc. Class Action Deadline March 13 - Investors Notified to Contact BFA Law to Protect Your Rights

New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

CRWV CLASS ACTION: Did CoreWeave, Inc. Mislead Investors? BFA Law Notifies Investors to Contact the Firm by March 13 about the Filed Securities Class Action

ViroMissile Appoints Michael G. Wood as Chief Business Officer

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock